Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma

15-year experience at a single institute

Hei C. Jeung, SunYoung Rha, Sung Hno Noh, Jin S. Min, Byung S. Kim, Hyuncheol Chung

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

BACKGROUND. The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection. They also evaluated the effect of dose-related factors (delivered total dose/m2, actual dose intensity [ADI], relative dose intensity [RDI]) of this regimen on patient survival. METHODS. A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996. Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks. The toxicity and survival were evaluated. RESULTS. The median follow-up duration was 58 months. Sixty-four percent of the total patients and 71.7% of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities. The 5- and 10-year disease free survival rates of total 301 patients were 58.4% and 46.5%, and the overall survival rates were 62.1% and 50.5%, respectively. Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2% vs. 52.9%; P = 0.0005). The median ADI of 5-FU and doxorubicin were 349 and 11 mg/m2/week, and the median RDIs of 5-FU and doxorubicin were 0.87 and 0.83, respectively. Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival. However, ADI and RDI did now show any effect on survival. CONCLUSIONS. Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities. Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma.

Original languageEnglish
Pages (from-to)2016-2025
Number of pages10
JournalCancer
Volume91
Issue number11
DOIs
Publication statusPublished - 2001 Jun 1

Fingerprint

Fluorouracil
Doxorubicin
Stomach
Carcinoma
Survival
Drug Therapy
Adjuvant Chemotherapy
Disease-Free Survival
Survival Rate
Neoplasm Staging
Intravenous Injections
Dissection
Appointments and Schedules
Multivariate Analysis
Recurrence
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Jeung, Hei C. ; Rha, SunYoung ; Noh, Sung Hno ; Min, Jin S. ; Kim, Byung S. ; Chung, Hyuncheol. / Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma : 15-year experience at a single institute. In: Cancer. 2001 ; Vol. 91, No. 11. pp. 2016-2025.
@article{e813ab0b7d1d44b288cba9e21f72a21a,
title = "Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute",
abstract = "BACKGROUND. The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection. They also evaluated the effect of dose-related factors (delivered total dose/m2, actual dose intensity [ADI], relative dose intensity [RDI]) of this regimen on patient survival. METHODS. A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996. Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks. The toxicity and survival were evaluated. RESULTS. The median follow-up duration was 58 months. Sixty-four percent of the total patients and 71.7{\%} of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities. The 5- and 10-year disease free survival rates of total 301 patients were 58.4{\%} and 46.5{\%}, and the overall survival rates were 62.1{\%} and 50.5{\%}, respectively. Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2{\%} vs. 52.9{\%}; P = 0.0005). The median ADI of 5-FU and doxorubicin were 349 and 11 mg/m2/week, and the median RDIs of 5-FU and doxorubicin were 0.87 and 0.83, respectively. Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival. However, ADI and RDI did now show any effect on survival. CONCLUSIONS. Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities. Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma.",
author = "Jeung, {Hei C.} and SunYoung Rha and Noh, {Sung Hno} and Min, {Jin S.} and Kim, {Byung S.} and Hyuncheol Chung",
year = "2001",
month = "6",
day = "1",
doi = "10.1002/1097-0142(20010601)91:11<2016::AID-CNCR1227>3.0.CO;2-I",
language = "English",
volume = "91",
pages = "2016--2025",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "11",

}

Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma : 15-year experience at a single institute. / Jeung, Hei C.; Rha, SunYoung; Noh, Sung Hno; Min, Jin S.; Kim, Byung S.; Chung, Hyuncheol.

In: Cancer, Vol. 91, No. 11, 01.06.2001, p. 2016-2025.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma

T2 - 15-year experience at a single institute

AU - Jeung, Hei C.

AU - Rha, SunYoung

AU - Noh, Sung Hno

AU - Min, Jin S.

AU - Kim, Byung S.

AU - Chung, Hyuncheol

PY - 2001/6/1

Y1 - 2001/6/1

N2 - BACKGROUND. The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection. They also evaluated the effect of dose-related factors (delivered total dose/m2, actual dose intensity [ADI], relative dose intensity [RDI]) of this regimen on patient survival. METHODS. A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996. Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks. The toxicity and survival were evaluated. RESULTS. The median follow-up duration was 58 months. Sixty-four percent of the total patients and 71.7% of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities. The 5- and 10-year disease free survival rates of total 301 patients were 58.4% and 46.5%, and the overall survival rates were 62.1% and 50.5%, respectively. Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2% vs. 52.9%; P = 0.0005). The median ADI of 5-FU and doxorubicin were 349 and 11 mg/m2/week, and the median RDIs of 5-FU and doxorubicin were 0.87 and 0.83, respectively. Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival. However, ADI and RDI did now show any effect on survival. CONCLUSIONS. Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities. Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma.

AB - BACKGROUND. The authors evaluated the efficacy of adjuvant chemotherapy with 5-fluorouracil (5-FU) plus doxorubicin in gastric carcinoma after D2-3 curative resection. They also evaluated the effect of dose-related factors (delivered total dose/m2, actual dose intensity [ADI], relative dose intensity [RDI]) of this regimen on patient survival. METHODS. A total of 301 patients with Stage II to IV (en bloc resected T4b; 1984 American Joint Committee on Cancer staging) were accrued between 1984 and 1996. Chemotherapy was started within 4 weeks of surgery according to the following schedule: intravenous bolus injection of doxorubicin 40 mg/m2 every 3 weeks for 12 cycles and 5-FU 400 mg/m2 weekly for 60 weeks. The toxicity and survival were evaluated. RESULTS. The median follow-up duration was 58 months. Sixty-four percent of the total patients and 71.7% of the patients who did not experience recurrence during the chemotherapy finished the protocol completely with acceptable toxicities. The 5- and 10-year disease free survival rates of total 301 patients were 58.4% and 46.5%, and the overall survival rates were 62.1% and 50.5%, respectively. Treatment completion group showed survival benefit over the early termination group in 5-year survival (75.2% vs. 52.9%; P = 0.0005). The median ADI of 5-FU and doxorubicin were 349 and 11 mg/m2/week, and the median RDIs of 5-FU and doxorubicin were 0.87 and 0.83, respectively. Multivariate analysis demonstrated that completion of chemotherapy is an independent prognostic factor of both disease free and overall survival. However, ADI and RDI did now show any effect on survival. CONCLUSIONS. Adjuvant chemotherapy with 5-FU plus doxorubicin for 60 weeks after D2-3 dissection induced promising survival duration with acceptable toxicities. Full administration of the planned dosage of the combined drugs is recommendable as opposed to early termination of the chemotherapy in gastric carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=0035370811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035370811&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010601)91:11<2016::AID-CNCR1227>3.0.CO;2-I

DO - 10.1002/1097-0142(20010601)91:11<2016::AID-CNCR1227>3.0.CO;2-I

M3 - Article

VL - 91

SP - 2016

EP - 2025

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 11

ER -